Agios Pharmaceuticals AGIO Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$99.11M-11.0% | -$108.04M— | -$103.43M-111% | -$112.02M-16.5% | -$89.29M-9.5% | ||
| $1.36M+6.7% | $1.27M-7.4% | $1.37M+2.2% | $1.26M-21.0% | $1.28M-5.2% | ||
| $15.54M+36.8% | $14.12M+29.5% | $12.38M+11.1% | $14.69M+27.0% | $11.36M+23.0% | ||
| $5.56M+826% | $5.55M+460% | $43K— | $1.64M+431% | -$765K-219% | ||
| $2.17M+8.9% | $886K-25.4% | $1.19M-52.4% | $1.24M+43.4% | $1.99M-50.2% | ||
| -$4.99M-77.0% | —— | $1.81M-74.5% | $3.91M— | -$2.82M-297% | ||
| -$19.17M+26.6% | —— | —— | —— | -$26.1M-44.7% | ||
| $2.46M+15.6% | $945K-0.3% | —— | $1.62M+135% | $2.12M-48.1% | ||
| $0+100% | —— | —— | -$683K— | -$188K— | ||
| $3.26M+8.0% | $3.2M+7.9% | $3.14M+7.8% | $3.08M+7.7% | $3.02M+7.7% | ||
| -$4.46M-10.2% | -$4.31M-12.0% | -$4.25M-12.1% | -$4.18M-12.2% | -$4.05M-10.9% | ||
| -$118.92M-6.7% | -$96.21M+27.8% | -$88.15M-4.7% | -$77.12M-6.2% | -$111.49M-11.6% | ||
| $769K+0.4% | $1.12M+15.8% | $1.56M+271% | $875K+454% | $766K+443% | ||
| $148.18M-15.3% | $161.08M-18.8% | $174.98M-82.4% | $130.8M+25.1% | $174.9M-28.3% | ||
| $290.26M+0.7% | $252.27M+68.0% | $272.09M+72.7% | $220.64M+55.4% | $288.26M-21.8% | ||
| $141.31M+25.5% | $90.08M— | $95.56M-61.9% | $78.97M+112% | $112.59M-9.6% | ||
| $2.08M+28.4% | $2.56M-47.2% | $4.44M+68.2% | $65K-94.1% | $1.62M-72.4% | ||
| $2.08M+28.4% | $2.56M-47.2% | $4.44M+68.2% | $65K-94.1% | $1.62M-72.4% | ||
| $24.47M+801% | —— | $11.84M-93.0% | $1.91M+106% | $2.72M-91.1% | ||
| $4K-97.9% | —— | $65K+291% | $1.32M+1,786% | $188K+136% | ||
| $1.14M-15.1% | $1.75M-68.8% | $1.67M-55.2% | $2.42M-7.2% | $1.35M-46.7% | ||
| -$19.17M+26.6% | —— | —— | —— | -$26.1M-44.7% | ||
| -$4.46M-10.2% | -$4.31M-12.0% | -$4.25M-12.1% | -$4.18M-12.2% | -$4.05M-10.9% | ||
| $2.46M+15.6% | $945K-0.3% | —— | $1.62M+135% | $2.12M-48.1% | ||
| $3.26M+8.0% | $3.2M+7.9% | $3.14M+7.8% | $3.08M+7.7% | $3.02M+7.7% | ||
| $1.36M+6.7% | $1.27M-7.4% | $1.37M+2.2% | $1.26M-21.0% | $1.28M-5.2% | ||
| $28K+1,300% | $118K— | -$2K-113% | $0-100% | $2K-98.7% | ||
| $290.26M+0.7% | $252.27M+68.0% | $272.09M+72.7% | $220.64M+55.4% | $288.26M-21.8% | ||
| $2.08M+28.4% | $2.56M-47.2% | $4.44M+68.2% | $65K-94.1% | $1.62M-72.4% | ||
| $668K+202% | —— | $214K+1,026% | —— | $221K— | ||
| -$4.46M-10.2% | -$4.31M-12.0% | -$4.25M-12.1% | -$4.18M-12.2% | -$4.05M-10.9% | ||
| $4K-97.9% | —— | $65K+291% | $1.32M+1,786% | $188K+136% | ||
| -$119.69M-6.6% | -$97.33M+27.4% | -$89.71M-6.0% | -$78M-7.2% | -$112.26M-12.2% | ||
| -$119.69M-6.6% | -$97.33M+27.4% | -$89.71M-6.0% | -$78M-7.2% | -$112.26M-12.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Agios Pharmaceuticals's cash flow data come from?
- Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.